Jon Hopper, FRCSEd.
Chief Medical Officer
Jon Hopper joined Osiris in November 2014. Dr. Hopper has served as Vice President, Global Medical Director at Stryker Corp., where he coordinated clinical evaluation and trials, and provided guidance on clinical aspects of risk management, design control, and product development. Prior to joining Stryker, Dr. Hopper spent almost five years in wound care with ConvaTec Inc., serving as Vice President of Medical Affairs, North America and Asia Pacific. Earlier in his career, he was Senior Medical Officer at the Devices Clinical Team of MHRA (the UK Regulatory Agency for medicines and medical devices) and practiced medicine as a trauma and orthopaedic surgeon. Dr. Hopper graduated with an M.B. Ch.B. from Birmingham University Medical School UK, is a fellow of the Royal College of Surgeons of Edinburgh, and attained an M.B.A. at Keele University UK.
I'm truly amazed at the orchestra being assembled, each with unique and special talents practicing each and everyday for the opening ceremony.
Have you ever heard such beautiful sound that masterfully touches the roots of our soul.
Not every day we are given the opportunity to participate with great wonderful people and better mankind forever and most will never know. We are special and chosen and we must make it our priority to share the powerful knowledge we have and gain, not just investors but everyone that crosses our path. OSIRIS products are life saving and life changing.
Not only do we have the privilege and opportunity to have direct impact on people needing these miracle producing products but also everyone else in their lives.
The lab is open for business and what new songs and music may they be orchestrating?
Most of us have no idea of what we own and the greatness we are about to disclose today. It is our obligation.
GRAFIX like no other
CARTIFORM like no other
OSIRIS restores health and wealth with simple tiny little stem cells more complex than the universe itself.
Sentiment: Strong Buy
Insisting to be right and disregarding reality. Remember the days when cash burn was the talk of the day and how many quarters it would take to eat that up. Those days are gone forever.
3, 5 and 10 years outlook. Cash, more cash and cash we don't know what to do with.
OSIRIS will again own prochymal.
Peter is no dummy, just a fantastic talented Swiss ventriloquist keeping his mouth shut. OSIRIS will be 1,000 times bigger than has ever been discussed on this board.
OSIRIS knows more about stem cells than all stem cell Co put together, they have safely and effectively administerd more stem cells than all other stem cell Co combined. The biggest amazing fact is that OSIRIS has saved more lives than all other stem cell Co combined.
Alla is a STAR
Lode is a STAR
Phil is a STAR
Jon is a STAR
Welcome to the universe named OSIRIS
Sentiment: Strong Buy
When the market goes against the market makers there is only one thing to do, yep cut your losses and move on.
Yep 25% moves on no news happen everyday on Wall St., $25.44 or $15 which will it be?
It will take only a smart or weak individual to ignite the wick and soon the rest will follow suit.
The right decision can cost a small fortune and a restful night sleep but for some it could cost them their life savings and more. Everyone has their pain thresholds and for some the pain becomes so great that it imobilizes the individual.
A small bump at $27 then on up to the battle field $29.29 and a day of capitulation of 5,000,000+ shares traded in one day.
Prepare yourselves $18.50 is not out of the equation and so $100, $200 or more is not either.
The information is available for everyone to see and use to their best discretion.
The sale will soon be over, buy now to eliminate any disappointing moments in the near future.
Stem cells are the future and the future is now. Take part and own OSIRIS
Sentiment: Strong Buy
Let's get the known and easy stuff out of the way, aside the great talented and professional people from Peter F. on down to the clean up crew, OSIRIS is bulging with money and drugs and is soon to get much much more of both as far into the future as one is willing to see, and what does Wall Street love more than money and drugs? Yep, more money and drugs, legal or otherwise.
OSIRIS, the precious gem that continues to be more precious, valuable and in high demand is tainted with illegal money betting on complete failure,
The GENIE and Stem Cells are out of the bottle and we all know exactly what is happening, the genie is a dud and the cells are multiplying faster than a super computer can count them, sorry for the disappointing realty but there's NO instant gratification here, just simple planning and precise execution.
There are no written or spoken words to describe of what OSIRIS has accomplished in just a few short years and not enough space here to list them all.
Now for the unknown, which is very simple and acceptable. When will the shorts exit the denial faze and enter the reality zone? When will they turn the genie into a superstar granting wishes to the wishful?
So what is one to do with such complex science and unpredictable Wall St.? Purchase a boarding pass, the new state of the art USS OSIRIS and new ADMIRAL LODE are about to embark on a JOURNEY of life transforming splendor.
OSIRIS traveling where no Stem Cell has traveled before in living color.
Patience will provide you with everything and more.
Not if but when. Will you still be holing the boarding pass when denial fades and reality sets in?
Sentiment: Strong Buy
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
June 8, 2015 9:12 PM
NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe, reduced damaging inflammation, and preserved or improved renal function over at least 24 weeks.
The results were presented at the late-breaking scientific sessions of the 75th annual meeting of the American Diabetes Association (ADA) currently being held in Boston. The ADA annual meeting brings together approximately 14,000 participants, including clinicians and researchers from 124 countries.
The trial's lead investigator, Associate Professor David Packham, Department of Medicine, University of Melbourne, and Director of the Melbourne Renal Research Group, stated that: "The results show that Mesoblast's allogeneic cell therapy was safe and may be particularly useful in patients with moderate to severe diabetic nephropathy, a disease which, despite all existing therapies, continues to have a high rate of progression to dialysis or transplantation, and to portend a high risk of death from cardiovascular disease."
Diabetic nephropathy affects 40-50 per cent of patients with type 2 diabetes and accounts for about 40 per cent of all patients with end-stage renal disease (kidney failure). It is thought to be caused by ongoing monocyte inflammation and endothelial dysfunction (abnormal blood vessels) in the kidneys. Mesoblast's bone marrow-derived MPCs are potent modulators of monocyte inflammation, and have been shown in preclinical studies to reduce monocyte infiltration in diabetic kidneys and to reverse endothelial dysfunction. Consequently, Mesoblast is developing MPC-300-IV for intravenous delivery in the treatment of diabetic nephropathy.
MPC-300-IV was evaluated in a double-blind, randomized, placebo-controlled, dose-escalating Phase 2 trial of 30 patients with type 2 diabetes and moderate to severe renal impairment, stage 3b-4 chronic kidney disease (CKD), who were already on a stable regimen of the standard of care therapy for diabetic nephropathy (renin-angiotensin system inhibition with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers). Patients received a single infusion of 150 million MPCs, 300 million MPCs, or saline control.
The objectives of the trial were to evaluate safety and to explore potential efficacy signals of MPC treatment on renal function. The pre-specified primary efficacy endpoint was to evaluate effects of MPC treatment relative to placebo on renal functional decline at 12 weeks, as defined by change in glomerular filtration rate (GFR) measured both by direct isotope scan and by serum-creatinine based estimation, and then for an additional 48 weeks of follow-up. Pre-specified secondary analyses included GFR differences between treatment and placebo groups with baseline GFR greater than 30ml/min/1.73m2 (stage 3b CKD, accounting for 60 per cent of enrolled patients), and treatment-related effects on the monocyte-derived cytokine interleukin-6 (IL-6), a major inflammatory marker associated with renal failure progression and adverse cardiovascular outcomes.
The primary efficacy endpoint of decline or change in GFR was in line with the 2012 joint workshop held by the United States Food and Drug Administration and the National Kidney Foundation which recommended that time to 30-40 per cent decline in GFR is an acceptable primary endpoint for evaluating potential benefits of new therapies for this patient population (Levey et al. GFR decline as an endpoint in clinical trials for CKD. American Journal of Kidney Disease 2014:64(6):821-835). This joint workshop recognized the significant unmet medical need and urgency to make new therapies accessible to patients who may benefit from them. This revised endpoint could make new treatments available earlier to patients with chronic renal failure by reducing trial size and duration, compared with the previously accepted composite endpoint of time to first occurrence of doubling of serum creatinine (equivalent to a 57 per cent reduction in GFR), renal replacement or death.
Key findings at 12 and 24 weeks in the MPC-300-IV trial were:
-- Safety profile for MPC treatment was similar to placebo, with no treatment-related infusion or other events.
-- Efficacy testing showed that MPC-treated subjects had improved renal function relative to placebo, as defined by preservation or improvement in GFR at both 12 and 24 weeks; these effects were seen even though this trial was not powered to show statistical significance of treatment.
-- While all three groups had similar mean GFR at baseline, 34.6, 35.7 and 34.6 ml/min/1.73m2, at 12 weeks the placebo group showed a decline in measured GFR of 4.0 ml/min/1.73m2 and 3.9 ml/min/1.73m2 relative to the groups receiving a single infusion of either 150M MPC or 300M MPC, respectively; the difference in creatinine-based estimated GFR decline between placebo and the 150M group reached significance (p equals 0.05).
-- By isotope-measured GFR, in patients with GFR greater than 30 ml/min/1.73m2 at baseline the placebo group showed a GFR decline at 12 weeks of 6.2 ml/min/1.73m2 relative to the pooled MPC-treated patients (p=0.07).
-- By creatinine-based estimated GFR, the placebo group with GFR greater than 30 ml/min/1.73m2 at baseline showed a GFR decline at 12 weeks of 4.5 ml/min/1.73m2 and at 24 weeks of 4.6 ml/min/1.73m2 relative to the pooled MPC-treated patients (p equals 0.04 and p equals 0.13, respectively).
-- There was a correlation between increased baseline IL-6 levels and improvement at 12 weeks in both serum creatinine and GFR (r equals 0.57, p equals 0.008) in MPC-treated patients.
-- MPC treatment was associated with a dose-dependent inhibition of IL-6 increase over 12 weeks; serum IL-6 levels increased by 2.5 pg/dl at 12 weeks in the placebo group compared to a reduction of 0.2 pg/dl in the 300M MPC group (p equals 0.01).
Key study conclusions were:
-- The safety profile and the potential efficacy signals of allogeneic MPC therapy for prevention or reversal of renal functional decline in diabetic nephropathy supports advancing the clinical program in patients with the highest medical need, e.g. rapid progression towards dialysis or renal transplantation, defined as an annual GFR decline of 5ml/min/1.73m2, and high risk of cardiovascular events.
-- Positive response to MPC therapy may be enhanced by the presence of viable, but at-risk, renal tissue and an aberrant pro-inflammatory milieu in the kidney.
-- Baseline GFR greater than 30 ml/min/1.73 m2 and high interleukin-6 (IL-6) levels may be biomarkers that predict efficacy with MPC treatment.
-- Reduction in IL-6 levels suggests that the mechanism of action by MPCs may involve reduction of pro-inflammatory M1 monocyte cytokines in the diabetic kidney.
-- MPC therapy may have applications in diverse renal conditions where inflammation plays a central role.
Mesoblast Chief Executive Silviu Itescu said: "We are very encouraged by the safety profile and the sustained efficacy signal that we have seen over 24 weeks after a single intravenous infusion of our allogeneic cell-based therapy in patients with diabetes and advanced chronic kidney disease. The growing burden of diabetic nephropathy and its impact on healthcare make this an important disease target for Mesoblast and our technology. We will specifically evaluate whether MPC-300-IV can alter the natural course of the disease in patients with rapid progression towards dialysis or renal transplantation, and will focus on early access regulatory pathways for developing this product."
Diabetic nephropathy is the single leading cause of end-stage kidney disease, accounting for nearly half of all end-stage kidney disease cases in the United States and over 40 per cent of new patients entering dialysis treatment. There were almost 2 million cases of advanced diabetic nephropathy in 2013. With the current diabetes population exceeding 20 million, over 6 million new patients are expected to develop diabetic nephropathy in the United States alone. Staging of CKD is based on absolute levels of GFR, and GFR decline is on the path of progression to kidney failure (stage 5, GFR less than 15ml/min/1.73m2). The current standard of care (renin-angiotensin system inhibition with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers) only slows the rate of progression to kidney failure by 16-25 per cent, leaving a large residual risk for end-stage kidney disease. For patients with end-stage kidney disease, the only treatment option is renal replacement (dialysis or kidney transplantation) which incurs high medical costs and substantial disruptions to a normal lifestyle. Due to a severe shortage of kidneys, in 2012 approximately 92,000 persons in the United States died while on the transplant list. For those on dialysis, the mortality rate is high with an approximately 40 per cent fatality rate within two years.
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) is a global leader in regenerative medicine. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late stage product candidates. Mesoblast's allogeneic or 'off-the-shelf' cell product candidates target significantly advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic/inflammatory disorders and oncology/hematology conditions. The lead therapeutic product candidates under investigation include MPC-150-IM for chronic congestive heart failure; MPC-06-ID for chronic discogenic low back pain, MSC-100-IV for acute graft versus host disease, and MPC-300-IV for biologic refractory rheumatoid arthritis, and diabetic nephropathy.
Global Head of Corporate Communications
T: +61 (0) 3 9639 6036
Sentiment: Strong Buy
I hope I will be able to get some sleep tonight, I always find it difficult to quiet my mind as it races fast in every direction. The best part I enjoy most at the annual pilgrimage is seeing all of the fellow OSIRINS owners and their families as we gathering after the meeting at our usual spot, as we share notes and comments and digest the information just received over good food and refreshments. I look forward every year to see my friends, make new acquaintances an hopefully new friends.
The garden is transforming and has recently been enlarged along with new planting, growing, harvesting and cell rotation along with new added greenhouse for increased production, new seeds discovery and new methods being implemented to deliver this bountiful cornucopia and record crop to market.
Weather patterns are improving and becoming more predictable, the organic way has proved to be the correct method and will result in successes in the foreseeable future and beyond. With continuing innovation and improved processes we will ultimately achieve our goal of recreating the garden of Eden here on earth and sharing it to all with joyful hearts.
Sentiment: Strong Buy
Many of people have traveled to the far reaching corners of the world and everything in between looking for the ultimate investment and never finding it, when all they needed to do was to look right in their back yard.
You need to look no further than OSIRIS. Purchase all you can afford often. You will not regret your investment 10-20 years out.
Stem cells does the body good, OSIRIS does the bank account good.
Sentiment: Strong Buy
We are living in the future and I'll tell you how I know because I read it in the paper 10 years ago.
(It's OK Jimmy don't cry, let me put an OSIRIS insta-heal bandage on it just like we did last week and it will be healed by morning. Thanks mom, your the greatest. Thank you Jimmy good night)
The World in 2025: 8 Predictions for the Next 10 Years
5. Disruption of Healthcare
Existing healthcare institutions will be crushed as new business models with better and more efficient care emerge. Thousands of startups, as well as today's data giants (Google, Apple, Microsoft, SAP, IBM, etc.) will all enter this lucrative $3.8 trillion healthcare industry with new business models that dematerialize, demonetize and democratize today's bureaucratic and inefficient system.
Biometric sensing (wearables) and AI will make each of us the CEOs of our own health. Large-scale genomic sequencing and machine learning will allow us to understand the root cause of cancer, heart disease and neurodegenerative disease and what to do about it. Robotic surgeons can carry out an autonomous surgical procedure perfectly (every time) for pennies on the dollar. Each of us will be able to regrow a heart, liver, lung or kidney when we need it, instead of waiting for the donor to die.
Sentiment: Strong Buy
Dr. Alla has the magic sauce..............build it and they will come
''we continue to learn every day the tremendous power adult stem cells have on the human body'' Ativaloc 6-7-15
OVATION a little dab or squirt will do it.
Sentiment: Strong Buy
OSIRIS making our world better one Stem Cell at a time. One small cell impacting our lives in enormous ways OSIRIS 23 remarkable years of making FIRST and counting
OSIRIS transforming science, technology and healthcare like no other
DFU's NO more a thing of the past
VLU's NO more a thing of the past
MICROFRACTURES NO more a thing of the past
OSIRIS stem cell coated medical devices OSIRIS
Did I mention OFF LABEL?
Open heart surgery......wrap your loving heart with GRAFIX
C-section scars never to be seen again.......GRAFIX again
Cosmetic surgery will never be the same
OSIRIS GRAFIX fast healing NO scaring, NO infections, NO inflammation, and like NO other OSIRIS GRAFIX
Back or joints pain NO more
Better and improved OVATION available at a clinic near YOU
Dr. Alla says, the lab is open for business and medical innovation
OSIRIS fostering imagination and creating novel effective medicine
Sentiment: Strong Buy
They do have Vision
They do have Talent
They do have $$$$$$$$$$$$$$$$$$$$$$$$$$$$
They do have Integrity
They do have Professionalization
They do have Best in Class Technology
They do have Solid Science light years ahead of all other wound companies combined
They do have Intellectual Property
They do have Influential Friends
They do have Leadership
They do have Resources
They do have __________________
OSIRIS Stem Cells......History in the making, the Future has never been Brighter.
The right Field, The right Time, The right Disruptive technology the Medical Industry has ever known!!!
Yes OSIRIS has done it again and again and will continue to do so in the near and distant future, being first is their CULTURE.
Now you have the privilege to see, hear and be part of the Medical REVOLUTION
Google this watch?v=XffP0qkFUx0
It will be the best hour of your life Yep, OSIRIS DOES IT AGAIN cuts healed overnight without pain, infections or scarring
Sentiment: Strong Buy
Maybe a yahoo thing................no ligit broker would force you to pay.......it would certainly raise the bar for the all time high to ever be broken again. all is fine my goal $5,000.00 in 10 years........stems will be hot one day on wall st and it will spike.................... that's my story and I'm sticking to it.
Sentiment: Strong Buy
check this out quick
Prev Close: 19.01
Bid: 14.50 x 300
Ask: 200,000.00 x 100
1y Target Est: 23.50
Earnings Date: Aug 5 - Aug 10 (Est.)
I have never seen this on yahoo $200,000.00 ask before
Sentiment: Strong Buy
Fixing the joints
Damaged ankles can be fused or replaced, but these surgeries have drawbacks
By Nancy Rome
Special to The Washington Post
Tuesday, March 16, 2010
The best athlete I knew in college has just had both his hips replaced. Another friend recently got two new titanium knees. We're all in our 50s -- once among the fittest in our college classes and now suffering from the kind of worn-out, creaking joints that generally come at a much older age.
Fixing the joints: Revolution on a small scale
Why are ankles so hard to replace?
Fixing the joints: Hip or knee, fine. But try getting a new ankle.
View All Items in This Story
Even though I stopped playing lacrosse in 1978, I have spent the past three decades wearing out ankles made unstable by the frequent turns that sport demanded. All the cartilage in my right ankle has eroded, and there's not much remaining in the left. I'm now "bone-on-bone," as the specialists say. A formerly fit 53-year-old, I now have severe osteoarthritis. I can walk only about a dozen city blocks; I take wheelchairs in most airports and museums; and I often have to sit down suddenly in the grocery store or garden when the pain becomes intolerable.
Determined not to give up every sport I love, I've sought treatment and canvassed the ankle gurus in Baltimore, where I live. After a series of appointments with specialists, one cortisone shot, two courses of hyaluronic acid injections (a viscous fluid designed to temporarily replace the body's joint lubricants) and countless X-rays, the prognosis isn't great. They are not offering to give me new ankles in the same way my friends have been getting new hips and knees.
Here's why: Hips and shoulders are simple ball-in-socket joints, which give our limbs rotational movement. The much-injured knee allows only forward and backward motion. But ankles are far more complex: They are a combination of three bones, the tibia and fibula (large and small leg bones) and the talus (the ankle bone). The leg bones are shaped to allow the talus to slide back and forth and in circles, and the talus works inside a socket; this allows your foot to move in many directions, as anyone knows who has been instructed by a physical therapist to use her foot to write the alphabet in the air.
If the ankle is a triumph of evolutionary engineering, it is proving hard to replicate in the lab. Not only is this complex joint sometimes forced to bear nearly five times the body's weight, but it also resides in a thin "soft tissue envelope," which makes healing more difficult if you do have surgery.
Three inadequate options
The doctors discussed three options with me: Fuse the ankle, replace it, or -- and this was the choice they all encouraged me to make -- grin and bear the pain until ankle surgeries and technology catch up to the care available for other worn-out joints. Each of these options comes with a long list of associated problems, especially for someone my age who wants to remain active.
The first option, fusing (or arthrodesis), involves using screws to secure the tibia (and sometimes the fibula, too) to the talus bone (in most cases), which can alleviate much of the pain caused by bone-on-bone friction. Fusing eliminates up-and-down movement but preserves side-to-side movement and allows other bones in the foot to still move after surgery. The problem is that fusing adversely affects your gait and is likely to create arthritis in other parts of the foot. Fusing may also lead to back, hip and knee problems and usually leaves you with a joint not mobile enough to play tennis or golf.
Replacement (or arthroplasty) has been performed sporadically for about 30 years. Though the surgery has improved steadily in that time, it has still met with less success than other joint replacements, and many surgeons perform total ankle arthroplasty only as a last resort. About 7 to 9 percent of replacements fail, which usually leads to fusion, and in the worst cases can result in amputation of the foot. Ideal candidates for ankle replacement are in their mid-60s and inactive because even successful replacements don't seem to last as long or allow for as much physical activity as other replacement joints.
There are 36 devices on the market for ankle replacements, some available only in Europe, some only in the United States. The surgeons with whom I spoke, and those who have reported on the procedure through studies, primarily use just four of these. One doctor warned that it's important to remember that although there are studies and clinical trials for each of the prostheses, no study has compared the four with one another.
Some recent studies indicate that replacements compare favorably with fusing. But none of the surgeons across the country with whom I spoke was in a hurry to recommend them, citing erosion and the subsequent weakening of the bone around the prosthesis, and all worried about the difficulties of fixing a failed replacement.
It all sounds like a grim outlook for people like me suffering from worn-out ankles at an early age, but there are some promising developments that combine prosthetics with biotechnology: using the patients' own stem cells, harvested from their bone marrow, to encourage the bone and cartilage to grow into the replacement joint, thereby creating a more stable environment for the implant. Although this approach is still experimental and there aren't enough data yet to warrant its widespread use in ankles, the concept has shown early promise in repairing ligaments and tendons.
Surgeons are also trying prostheses made of more bone-friendly porous materials to encourage them to knit to the bones, and they're developing techniques that require less removal of the bone.
There are several ways in which doctors are trying to repair and rebuild the cartilage that those with osteoarthritis have lost. The most widely used is microfracture, in which tiny holes are drilled into the bone to release blood and bone marrow, which then begin to form new cartilage. One local specialist injects concentrated, bone-marrow-derived stem cells along with a collagen-based formula into the ankle to encourage cartilage growth. Others are experimenting with filling "potholes" in the ankle's cartilage, using a concoction of human cartilage and biological glue, but this method requires a donor for the replacement cartilage, which creates further complications.
What can we expect in the next five to 10 years? Surgeons I spoke to all anticipate that the technology for ankles will have caught up to the other joints to such an extent that younger and younger patients requiring relief from injured or deteriorating joints will at last be able to opt for replacements that will last longer and that can be repaired with fewer complications if they fail. The doctors also were quick to disclose that many of them have affiliations with biotech companies and therefore might be invested in the success of one technological advance over another.
For now, I've elected the grin-and-bear-it route. After losing 10 pounds and receiving two rounds of hyaluronic acid injections, I'm ready to try almost anything. I've been to a naturopath who has given me supplements: various forms of omega-3 fatty acids, glucosamine sulfate and a systemic enzyme that has shown promise in reducing inflammation in severely arthritic joints. These supplements do seem to be helping, because I notice what happens when I forget to take them: I can't walk as far.
Although there's no evidence that the supplements are helping me regrow my own cartilage, I've made some progress in terms of physical activity. I still find myself sitting down abruptly when the pain overwhelms me, but it is happening less frequently.
The exercises and body-awareness lessons of the Alexander Technique have also been very useful because they can keep you from becoming lopsided and help alleviate pain. Forced to stop yoga because I could no longer manage the standing poses, I can still do Pilates because much of it can be done without putting undue pressure on my ankles.
Acupuncture has helped, but it offers short-lived pain relief in my case. Massage therapy has been more helpful than anything else. I found a licensed massage therapist, specializing in orthopedic massage methods that can take the swelling and pain away from my ankles in about 15 minutes, and the effects last for days. A machine used by another massage therapist (a neuromuscular therapist in this case) called a Thera-Stim also offers relief, although the tingling of electric currents transmitted through rubber pads is not exactly pleasant.
A remarkable thing I've learned is that the slow deterioration of cartilage resulting in severe osteoarthritis can have as great an impact on quality of life, according to many studies, as more-dramatic medical conditions. As I come to terms with my altered status -- and try to limit my ibuprofen intake -- the biggest challenge is to prevent further damage and to halt the domino effect that can happen after one part of us wears out.
Rome is a writer and documentary filmmaker.
Sentiment: Strong Buy
Read between the lines and have a little imagination..........
Google this and see the video ... remember Dr. Mills?
''Jill Helms of Stanford University describes her stem cell research which aims to uncover ways to activate the stem cells in our bodies to help heal broken bones. Series: "California Institute for Regenerative Medicine"
Sentiment: Strong Buy
LOOKING TOWARD THE FUTURE OF STEM CELLS IN ORTHOPAEDICS
Dr. Thomas Einhorn and Dr. George Muschler weigh in on stem cell therapy, one of the hottest topics in orthopaedics today.
By Susan Doan-Johnson
The role biologics will play in the future of orthpaedic surgery remains uncertain.
Some promising biologics turned out to be disappointments. For example, a decade of research and clinical use of growth factors – namely, bone morphogenic proteins (BMPs) – did not pan out the way researchers had hoped.
“We were banking on BMPs changing orthopaedic surgery,” said Thomas Einhorn, MD, from Boston University, in a press conference at the recent American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting. BMPs, however, “have not lived up to the promise,” he said.
Thomas Einhorn, MD
But there are reasons to remain optimistic as the focus moves to cellular-based therapies – primarily stem cell therapy. Dr. Einhorn believes stem cells will not only be used to treat orthopaedic injuries, but will also be the foundation for drug discovery and research. They could, in fact, usher in an era of drug-based treatments for orthopaedic issues, he said.
3 Applications for Stem Cells
Dr. Einhorn’s particular interest is in how stem cells derived from bone marrow of adults can contribute to fracture healing. He began using autologous bone marrow grafting on fracture nonunions based on the positive results of a study by Hernigou et al , who achieved union in 53 of 60 patients with non-infected nonunions. In the study, bone marrow was aspirated from the patients’ iliac crests, centrifuged, and then reinjected as a bone marrow aspirate concentrate that contained progenitor and other mononuclear cells.
Stems cells can also be used to treat patients with osteonecrosis of the femoral head. At a forum on stem cells at the Annual Meeting, Dr. Einhorn shared his case series of patients with stage 1 or stage 2 osteonecrosis who were treated with stem cells. At 1 year of follow-up, 75% of these patients improved significantly without surgical intervention.
Dr. Einhorn is most excited about the possibilities for preventing progression of osteoarthritis of the knee – in fact, he referred to it as a “home run.” Human and animal studies have yielded positive results, he said, including pain reduction when compared with controls. The key, he said, will be to inject the stem cells where they are needed so that they are not washed away by synovial fluid.
Questions and Cautions
George Muschler, MD, from the Cleveland Clinic, agreed that stem cell therapy is one of the hottest topics in orthopaedic surgery today.
George Muschler, MD
He cautioned that much research is still needed to define how stem cells should be used in orthopaedic applications. This will take a concerted effort from a network of clinical investigators who are working together to answer questions about safety, efficacy, and long-term durability of stem cell therapy in orthopaedics, Dr. Muschler said.
One of the challenges will be the personal nature of stem cell therapy. Can stem cells be harvested and implanted from one person to another, or is autologous stem cell therapy the best option? Similarly, how will stem cells from one part of the body behave in different applications? For example, will avascular necrosis, osteoarthritis, and fracture nonunion respond the same way to the same type of stem cell?
Both Dr. Muschler and Dr. Einhorn believe the answer to the latter question is no. “We need to be prepared to wrestle with the fact that when we take a cell from its natural milieu and transplant it into another site, it may not behave as we expect,” Dr. Einhorn said.
The delivery vehicle could be an issue in this respect as well. Right now, most surgeons harvest the cells from the patient, centrifuge them, and then reinject them into the patient. This is a low-risk procedure, Dr. Muschler said.
But “surgeons may take cells and mix them with whatever vehicle they believe will work and then implant them,” Dr. Einhorn said. The problem is there is little data on which delivery vehicles are appropriate for the patient – some delivery vehicles could end up being toxic, or the stem cells and delivery vehicle could work against each other, rendering the treatment ineffective. This highlights the need for further research on stem cells and how they should be delivered to the patient, Dr. Einhorn said.
Encouraging Study Results
Research is ongoing, of course, and Dr. Einhorn and Dr. Muschler are encouraged by the recently published study by Vangsness et al.  The study showed that a single stem cell injection of adult human mesenchymal stem cells (MSC) following meniscus knee surgery could provide pain relief and aid in meniscus regrowth after partial medial meniscectomy.
C. Thomas Vangsness, Jr., MD
The study involved 55 patients, ages 18 to 60, who underwent a partial medial meniscectomy at seven medical institutions. Patients were randomly placed in one of three treatment groups:
Group A patients (18) received a “low-dose” injection of 50 million stem cells 7 to 10 days after meniscus surgery
Group B patients (18), received a higher dose of 150 million stem cells
Control Group patients (19) received sodium hyaluronate only
Patients were followed for 2 years to assess safety, meniscus regeneration through MRI and X-ray images, overall condition of the knee joint, and clinical outcomes. While most patients had some arthritis, patients with severe arthritis (level three or four) in the same compartment as the meniscectomy were excluded from the study.
Key findings of the study included the following:
No ectopic tissue formation or “clinically important” safety issues were identified.
As determined by MRI, there was “significantly increased meniscal volume” (defined as at least a 15% increase in meniscal volume) in 24% of patients in the low-dose injection group (A) and 6% of the high-dose injection group (B) at 1 year. There was no statistical increase in meniscal volume at 2 years.
No patients in the control group met the 15% threshold for increased meniscal volume.
Patients with osteoarthritis experienced a reduction in pain in the stem cell treatment groups; there was no reduction in pain in the control.
Additional Stem Cell Studies Presented at AAOS
Chondrogenesis Using Adipose-Derived Stem Cells and FDA-Approved Biomatrices
Matrix Assisted Autologous Chondrocyte Transplantation: Results at 10 Years Follow Up
Treatment of Cartilage Defects with a Novel RUNX-1 Inducing Molecule to Induce Chondrogenesis
Autologous Adipose Tissue derived Mesenchymal Stem Cells for the Treatment of Osteoarthritis of the Knee
Adipose-derived Stem Cells Promote Meniscus Regeneration
Hernigou P, Poignard A, Beaujean F, et al. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am. 2005;87(7):1430–7.
Vangsness CT Jr, Farr J 2nd, Boyd J, Dellaero DT, Mills CR, LeRoux-Williams M. Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy: a randomized, double-blind, controlled study. J Bone Joint Surg Am. 2014 Jan 15;96(2):90-8.
Susan Doan-Johnson is the Director of Editorial Content
Sentiment: Strong Buy
Disagree, short pressure is unimaginable. Most BIG and quick money is made to the down side............steady as she goes, money talks BS walks........earnings ....earnings ....earnings ....earnings ....earnings ....earnings
OSIRIS is made up with all the colors projected from the prism, the artist are hard at work now sorting the best materials that will become the masterpiece to be cherished by many for years to come.
Sentiment: Strong Buy
Truth.......Billions $$$$$$$$$ @ stake here $18.50 is the line in the sand. X $30 and we get to $130.00 by Xmas 2016
Decision to explore intl. locations was not by choice but by pressure.
Remember OSIRIS is the 800 lb. stem cell in the room, they've been at it for 22 years. Patience is KEY, anything under $50 is a gift. Accumulate now for $1,000+ in 5 years or less.
Switzerland here we come and all covered with chocolate............
Sentiment: Strong Buy
Close above $18.50 for three consecutive days takes us to all time highs above $30 in short order.
New 52 week high June 1, 2015 $$$$$$$$20.00
Sentiment: Strong Buy
Could this be the week we look back on and see the spark that set this rocket in motion?
The longer it lingers below $18.50 the bigger the catapult to higher levels will be. Suppressing the price at these levels will turn in a large $$$$$$$ loss for many individuals an firms alike.
There is nothing else to know, great management, great product, great gross margins.........$100.00 will be here sooner than you can say OSIRIS.
We all have done it, when we convince ourselves that it can't go any lower ant it does then we sell, only to look back and notice we sold at the bottom.
The difficulty comes in is when you short, the bottom is endless and the losses can be astronomical................is the fuse lit and rushing towards the sticks of dynamite? Or am I too quick to come to this conclusion because I'm a biased share owner.
This August OSIRIS will celebrate eight years as a public company and has never traded above $30.00....................things are about to change for the better, get your shares while you still can and afford them. Things will never be the same.
Sentiment: Strong Buy